AMGN · News · 20260910N

Market Demand Trends

AMGEN INC · 2026-09-10 · Importance 36 · Surprise 40

Amgen reported a broad growth rebound in the second quarter, with 22 products achieving at least double-digit sales growth. Tezspire and Repatha were identified as key accelerating products, indicating stronger demand in respiratory and cardiovascular markets. The reported product momentum supports improved demand across Amgen’s portfolio rather than reliance on a single product.

Key facts

• HSBC downgraded Amgen from Buy to Hold and lowered its price target due to valuation concerns. source
• NewEdge Advisors LLC reduced its stake in Amgen Inc. by 3% in Q2, retaining 93,040 shares valued at $33.69 million. source
• National Pension Service increased its stake in Amgen Inc. by 1.0% in the second quarter, bringing its total holdings to 1,286,149 shares valued at $465.74 million. source
• Sequoia Financial Advisors LLC increased its stake in Amgen Inc. by 4.5% in the second quarter, bringing its total holdings to 173,024 shares valued at $62.7 million. source
• Amgen stock recently dipped by 2.25%, underperforming the broader S&P 500. source
• Institutional investors own 76.5% of Amgen. source